CEO Dr. Hanadie Yousef shares more about our JuvNET Platform as an invited seminar speaker for Stanford’s CS 522: Artificial Intelligence in Healthcare course
CEO, Dr. Hanadie Yousef, had a rewarding experience moderating and participating in the panel titled “Rethinking Platform Biotech: How Emerging Innovators Are Structuring the Future of Pharma Collaboration” last week at Fierce Biotech Week
AI Excellence: Juvena’s JuvNET Platform Recognized as CEO Dr. Yousef Makes Prestigious Mayfield | Divot AI List
Juvena Therapeutics presented JUV-161 and JUV-112, at ENDO2025, earning recognition from the Endocrine Society for innovation in metabolic and endocrine health
Juvena Therapeutics’ Partnership with Eli Lilly Featured in Nature Biotechnology for Enhancing Muscle Health and Body Composition
Dr. Hanadie Yousef participates in the World Economic Forum’s Innovator Communities Meeting and Global Technology Retreat- and shares her expert insights on 2 panels: “Breaking Barriers: Funding Frontier Tech” and “Innovation to Impact: Commercialization Insights from the Field”
Director of Translational Biology and Pharmacology, Priya Handa, PhD, and Senior Director of Discovery and Platform, Thach Mai, showcased our research at the 23rd Biopharma Drug Discovery Nexus Conference in San Francisco
Pharmaceutical Executive Video Interview: Hanadie Yousef, PhD, Co-Founder and CEO Juvena Therapeutics, Inc. (Link to 5 video clips)
Watch all 5 clips now:
Expanding Disease Indications JUV161
Obesity Muscle Targeting Program
